Navigation Links
Neurocrine Biosciences Reports Third Quarter 2008 Results
Date:10/28/2008

istrative expenses is primarily due to cost savings related to recent restructurings.

The Company's balance sheet on September 30, 2008 reflected total assets of $207.7 million, including cash and investments of $118.2 million compared with balances at December 31, 2007 of $276.7 million and $179.4 million, respectively. The Company expects to end 2008 with approximately $100 million in cash and investments.

"We are pleased with the progress of our GnRH program, especially the recent positive results of our 603 study where once a day elagolix showed profound efficacy with minimal impact on bone mineral density. We are also nearing completion of the final preclinical studies of urocortin 2 to allow for long-term Phase II clinical studies and our scientists have just recently identified a clinical candidate from our VMAT2 development program for movement disorders," said Kevin Gorman, Chief Executive Officer and President of Neurocrine Biosciences. "While we are making great strides in advancing our pipeline, we continue to prioritize expenditures and diligently manage our cash burn."

R & D Pipeline Update

Neurocrine's clinical development group and corporate partners have five programs in clinical development. Neurocrine scientists continue to supply Neurocrine's pipeline to meet the Company-wide goal of bringing one new compound into development each year.

Elagolix for Endometriosis

The Company recently announced the positive safety and efficacy results from the completed 6-month treatment phase of its Phase IIb clinical trial (PETAL Study) using its proprietary, orally-active nonpeptide Gonadotropin-Releasing Hormone (GnRH) receptor antagonist, elagolix.

The primary endpoint, percent change from baseline in mean bone mineral density (BMD) demonstrated elagolix did not induce significant bone loss over the six month treatment period. Additionally, elagolix also met the secondary endpoints of improvement in endometrios
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Webcast Alert: Neurocrine Announces 3Q 08 Financial Results
2. Neurocrine Biosciences to Present at the Oppenheimer 19th Annual Healthcare Conference
3. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2008 Financial Results
4. Neurocrine Biosciences to Present at the UBS Global Life Sciences Conference
5. Neurocrine Biosciences to Present at Thomas Weisel Healthcare Conference and the NewsMakers in the Biotech Industry Conference
6. Neurocrine Biosciences Reports Second Quarter 2008 Results
7. Neurocrine Biosciences Announces Conference Call and Webcast To Present Second Quarter 2008 Financial Results
8. Neurocrine Biosciences to Present at the 2008 Citi Investment Research Global Health Care Conference
9. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2008 Financial Results
10. Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year End 2007 Financial Results
11. Neurocrine Announces Appointment of Kevin Gorman, Ph.D., as President and Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... , March 6, 2015 ...   2011 von der Assistance Publique - ... initiiert., Sie ist eine französische, gemeinschaftliche, randomisierte ... Patienten rekrutiert wurden. Verglichen werden Patienten mit ... Yttrium-90 Harz-Mikrosphären oder Sorafenib behandelt wurden. Die ...
(Date:3/5/2015)... New York (PRWEB) March 05, 2015 ... veterans to be able to get an Advanced Semen ... money, stress, blaming and guessing are all risk factors ... assuming the woman is the source of the infertility. ... female. LifeCell Dx has the simplest, least complicated ...
(Date:3/5/2015)... Park, NC (PRWEB) March 05, 2015 ... announced that Pierre Noel, M.D., Professor of Medicine, ... to the Company’s Board of Directors. ... “We are extremely fortunate to have Dr. Noel, ... country’s leading healthcare organization, join Entegrion’s Board. His ...
(Date:3/5/2015)... -- In response to the incorrect assertions by LD, distributed ... on February 12, 2015. Impeto Medical SAS and its ... their SUDOSCAN® devices have been proven to provide accurate ... have the courts decide this dispute rather than the ... written by Key Opinion Leaders, published by significant peer-reviewed ...
Breaking Biology Technology:Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 2Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 3Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 4Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 5Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 6LifeCell Dx Offers New Option to Veterans with Infertility 2LifeCell Dx Offers New Option to Veterans with Infertility 3Entegrion Announces Appointment of Pierre Noel, MD, to Its Board of Directors 2Impeto Medical Responds to Published Allegations by LD Technology LLC ("LD") 2
... ... Vein and Skin Care Center. Tokyo Vein Clinic visited , for a close up look at ... back to patients in Japan. , ... June 16, 2010 -- The Japanese have a long history of being on the cutting edge. ...
... ... found dead four days after receiving the Gardasil vaccine has filed an amicus ... asked to bar lawsuits against manufacturers of defectively designed vaccines. The mother ... a lessened incentive to produce a safe vaccine and public trust in the ...
... ... ... The American Medical Writers Association named medical writer, Rita Buckley, Writer/Owner of medical ... Medical Communication. She received the awards for The Lehman Series Expert Panel on Weight ...
Cached Biology Technology:OnychoLase Laser Nail Centers Making a Global Impact, By Bringing Western Medicine To The East 2Supreme Court Amicus Brief Filed Opposing Lawsuit Protection for Manufacturers of Defectively Designed Vaccines 2Medical Writer Rita Buckley Wins Awards for Excellence in Medical Communication 2Medical Writer Rita Buckley Wins Awards for Excellence in Medical Communication 3
(Date:2/5/2015)... North Carolina , 5. Februar 2015 ... Jahr als spezialisiertes Logistikunternehmen und hat eine ... einzige klinische Logistikfirma (Clinical Logistics Organization – ... der neuen Kampagne lautet First , ... Foto: http://photos.prnewswire.com/prnh/20150205/173753 ...
(Date:2/5/2015)... --  Epic Sciences , a precision diagnostics company dedicated to ... Prahalad , Ph.D., president and CEO, is scheduled to present ... Silicon Valley, which is taking place at the Computer History ... January 26-28, 2015. Dr. Prahalad will give ... year, Epic Sciences was a finalist in the PMWC,s Most ...
(Date:2/5/2015)... , Jan. 27, 2015   Marvin ... globally deployed, innovative test solutions for military, ... delivery of its TS-323 GENASYS Test ... Company (LMSSC). GENASYS is a high-performance PXI-based ... mission-critical applications that require performance functional testing. ...
Breaking Biology News(10 mins):Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4
... 2012 In 2012 Wiley-Blackwell, the Scientific, Technical, Medical, ... Inc., will begin publishing 44 titles new to its ... published in collaboration with societies or other organizations. ... the course of 2012 include Advanced Healthcare Materials ...
... the aid of light: this is made possible ... of neurobiological processes with unprecedented spatial and temporal ... light-activated protein channelrhodopsin. Biophysicists from Bochum and Berlin ... through an interdisciplinary approach. The researchers report on ...
... drug may be useful in fighting malaria, researchers report in ... protozoa, the drug readily crosses into the red blood cells ... works at very low concentrations with no observed toxicity to ... of the National Academy of Sciences . The researchers ...
Cached Biology News:Wiley-Blackwell adds 44 titles to journal publishing program in 2012 2Optogenetic tool elucidated 2Modified bone drug kills malaria parasite in mice 2
... dihydrochloride) is a fluorescent counterstain ... in color. The bright blue ... red fluorochromes such as rhodamine, ... DAPI can be used for ...
... sets of glass plates, bar clamp, and ... features of these units are:, safety interlock ... reservoirs , upper and lower reservoirs have ... safe disposal of buffer solutions , leveling ...
... P450 (CYP450) metabolite postulated to play an ... vasculature. In rat cerebral microvessels, 20-HETE is ... 20-HETE is excreted mainly as the glucuronide ... pg/ml in human urine) is about 10-fold ...
... sensitive silver stain. Reproducible ... baths or reversers needed. ... polysaccharides. Linear protein-to-stain color ... multiple gels per tray. ...
Biology Products: